Lipigon signs target validation agreement with Secarna Pharma
The UBI alumni Lipigon Pharmaceuticals announced yesterday that the startup has entered into a target validation research agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals. The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases.
